Alterations of Glutathione and GSTM1 Mutation Induce Tumor Metastasis and Invasion Via EMT Pathway in Breast Cancer Patients
Objectives: Alteration in the Glutathione (GSH) and Glutathione S-Transferase (GST) family lead to various disorders including breast cancer. However, the role of GSH and GSTM1 in the onset of breast cancer is still not fully elucidated. In the present study we observed considerable deficiency in the levels of glutathione and genetic mutation in the GSTM1 enzyme that influence susceptibility to breast cancer metastasis and invasion via EMT pathway.
Methods: GSTM1 genotype was identified by multiplex polymerase chain reaction (PCR), real time (RT)-PCR and western blotting in breast tumor samples and adjacent normal control tissue (ANCT) samples. The endogenous glutathione levels were determined by high performance liquid chromatography (HPLC).The tumor metastasis, invasion and epithelial-mesenchymal transition (EMT) biomarkers were determined by RT-PCR.
Results: In present study genotyping analysis of GST investigated that genetic mutation in GSTM1 was detected in breast cancer tissue samples. mRNA and protein expression of GSTM1 was significantly downregulated in tumor samples as compared to adjacent normal control tissue (ANCT) samples in breast cancer patients. Significant reduction of total glutathione (GSHt P<0.05) was observed among correlation with patient ages, stages and histological grades of breast cancer patients. Additionally, downregulation of GSTM1 promotes EMT pathway that leads to enhanced the expression of tumor proliferation, invasion and metastasis in breast cancer patients (p<0.05).
Conclusion: The present findings suggest that GSTM1 genotype could be a potential biomarker for breast cancer pathogenesis.
1.Malik FA, Sanders AJ, Jones AD, Mansel RE, Jiang WG. Transcriptional and translational modulation of KAI1 expression in ductal carcinoma of the breast and the prognostic significance. Int J Mol Med 2009;23:273–8.
2. Ward E, Jemal A, Thun M. Regarding “Increase in breast cancer incidence in middle-aged women during the 1990s”. Ann Epidemiol 2005;15:424–5; author reply 6–7. [CrossRef]
3. Gherghel D, Griffiths HR, Hilton EJ, Cunliffe IA, Hosking SL. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2005;46:877–83. [CrossRef]
4. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004;137:62–9. [CrossRef]
5. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S-transferase family of enzymes. Mutat Res 2001;482:21– 6. [CrossRef]
6. Huang J, Tan PH, Tan BK, Bay BH. GST-pi expression correlates with oxidative stress and apoptosis in breast cancer. Oncol Rep 2004;12:921–5. [CrossRef]
7. The diabetes prevention program: evaluation and management of diabetes. Response to Adler and Turner and Singer et al The DPP Research Group. Diabetes Care 1999;22:1757–8.
8. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006;25:1639–48. [CrossRef]
9. Suvakov S, Damjanovic T, Stefanovic A, Pekmezovic T, SavicRadojevic A, Pljesa-Ercegovac M, et al. Glutathione S-transferase A1, M1, P1 and T1 null or low-activity genotypes are associated with enhanced oxidative damage among haemodialysis patients. Nephrol Dial Transplant 2013;28:202–12.
10. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733–43.
11. Chirila DN, Balacescu O, Popp R, Oprea A, Constantea NA, Vesa S, et al. GSTM1, GSTT1 and GSTP1 in patients with multiple breast cancers and breast cancer in association with another type of cancer. Chirurgia (Bucur) 2014;109:626–33.
12. Qiu LX, Yuan H, Yu KD, Mao C, Chen B, Zhan P, et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects. Breast Cancer Res Treat 2010;121:703–8. [CrossRef]
13. Yang Y, Parsons KK, Chi L, Malakauskas SM, Le TH. Glutathione S-transferase-micro1 regulates vascular smooth muscle cell proliferation, migration, and oxidative stress. Hypertension 2009;54:1360–8. [CrossRef]
14. Mishra A, Chandra R, Mehrotra PK, Bajpai P, Agrawal D. Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg Today 2011;41:471–6. [CrossRef]
15. Strauss WM. Preparation of genomic DNA from mammalian tissue. Curr Protoc Neurosci. 2001;Appendix 1:Appendix 1H.
16. Bogaards JJ, van Ommen B, van Bladeren PJ. An improved method for the separation and quantification of glutathione S-transferase subunits in rat tissue using high-performance liquid chromatography. J Chromatogr 1989;474:435–40.
17. Cabello CM, Bair WB, 3rd, Wondrak GT. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 2007;8:1022–37.
18. Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013;2013:972913.
19. Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, et al. Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem 2005;280:6950–9. [CrossRef]
20. Knight JA. The biochemistry of aging. Adv Clin Chem 2000;35:1–62. [CrossRef]
21. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 1991;52:287–305. [CrossRef]
22. Liang H, Zhou Z, Luo R, Sang M, Liu B, Sun M, et al. Tumor-specific activated photodynamic therapy with an oxidation-regu-lated strategy for enhancing anti-tumor efficacy. Theranostics 2018;8:5059–71.
23. Didziapetriene J, Kazbariene B, Tikuisis R, Dulskas A, Dabkeviciene D, Lukoseviciene V, et al. Oxidant/antioxidant status of breast cancer patients in pre- and post-operative periods. Medicina (Kaunas) 2020;56:70. [CrossRef]
24. Gudmundsdottir K, Tryggvadottir L, Eyfjord JE. GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 2001;10:1169–73.
25. Kano SI, Choi EY, Dohi E, Agarwal S, Chang DJ, Wilson AM, et al. Glutathione S-transferases promote proinflammatory astrocyte-microglia communication during brain inflammation. Sci Signal 2019;12:eaar2124. [CrossRef]
26. Chen ZH, Xian JF, Luo LP. Association between GSTM1, GSTT1, and GSTP1 polymorphisms and gastric cancer risk, and their interactions with environmental factors. Genet Mol Res 2017;16. [CrossRef]
27. Vaury C, Laine R, Noguiez P, de Coppet P, Jaulin C, Praz F, et al. Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res 1995;55:5520–3.
28. Pacholak LM, Amarante MK, Guembarovski RL, Watanabe MAE, Panis C. Polymorphisms in GSTT1 and GSTM1 genes as possible risk factors for susceptibility to breast cancer development and their influence in chemotherapy response: a systematic review. Mol Biol Rep 2020;4:5495–501. [CrossRef]
29. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65–70.
30. Marcucci F, Stassi G, De Maria R. Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov 2016;15:311–25.